匹莫苯丹
匹莫苯丹结构式
|
常用名 | 匹莫苯丹 | 英文名 | Pimobendan |
|---|---|---|---|---|
| CAS号 | 74150-27-9 | 分子量 | 334.372 | |
| 密度 | 1.4±0.1 g/cm3 | 沸点 | N/A | |
| 分子式 | C19H18N4O2 | 熔点 | 249 °C(dec.) | |
| MSDS | 中文版 美版 | 闪点 | N/A | |
| 符号 |
GHS06 |
信号词 | Danger |
|
Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivatives.
Bioorg. Med. Chem. 18 , 3985-91, (2010) A series of 1H-benzo[d]imidazole analogues of Pimobendan, substituted at position 5 with either -CF(3) or -NO(2), were synthesized using a short synthetic route. All the nitro derivatives were potent, and exhibited a concentration- and partial endothelium-dep... |
|
|
Valvular dysplasia and congestive heart failure in a juvenile African penguin (Spheniscus demersus).
J. Zoo Wildl. Med. 45(4) , 987-90, (2014) Abstract: An aquarium-housed, 6-mo-old African penguin (Spheniscus demersus) presented with acute respiratory distress. Auscultation revealed a grade II-III systolic murmur in the absence of adventitial sounds, and an enlarged heart without pulmonary edema wa... |
|
|
Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension.
J. Cardiovasc. Pharmacol. 65(6) , 640-8, (2015) This study was designed to assess the progression of pulmonary arterial hypertension (PAH) and the effectiveness of therapy using recently investigated echocardiographic parameters. PAH is characterized by the progressive elevation of pulmonary artery pressur... |
|
|
A review of the pharmacology and clinical uses of pimobendan.
J. Vet. Emerg. Crit. Care (San Antonio.) 22(4) , 398-408, (2012) To review the pharmacology, research developments, and clinical uses of pimobendanOriginal research articles and clinical studies from 1984 to August 2011.Pimobendan is approved for use in dogs for the treatment of congestive heart failure (CHF) secondary to ... |
|
|
In vitro effect of pimobendan on platelet aggregation in dogs.
Am. J. Vet. Res. 74(3) , 403-7, (2013) To determine whether pimobendan has in vitro antithrombotic properties through inhibition of platelets in canine blood samples.10 healthy adult dogs.Blood samples were collected from each dog into tubes containing hirudin or sodium citrate. Pimobendan was add... |
|
|
Canine dilated cardiomyopathy: a retrospective study of prognostic findings in 367 clinical cases.
J. Small Anim. Pract. 51(8) , 428-36, (2010) To review the association between clinical signs and diagnostic findings and the survival time of dogs with dilated cardiomyopathy (DCM), and any influence of treatment prescribed.A retrospective observational study of 367 dogs with DCM. Survival times until ... |
|
|
Current use of pimobendan in canine patients with heart disease.
Vet. Clin. North Am. Small Anim. Pract. 40(4) , 571-80, (2010) Pimobendan is a drug with both inotropic and vasodilatory properties and is widely used for the treatment of heart failure in dogs. The best evidence regarding its efficacy is derived from several clinical studies of dogs with the two most common conditions t... |
|
|
Effect of pimobendan on the clinical outcome and survival of cats with non-taurine responsive dilated cardiomyopathy.
J. Feline Med. Surg. 14(4) , 233-9, (2012) This retrospective study was designed to assess the effect of pimobendan on the median survival time (MST) of cats with non-taurine responsive dilated cardiomyopathy (DCM). Thirty-two client-owned cats with a left ventricular internal dimension at end systole... |
|
|
Effect of furosemide and high-dosage pimobendan administration on the renin-angiotensin-aldosterone system in dogs.
Am. J. Vet. Res. 74(8) , 1084-90, (2013) To determine whether a high dosage of pimobendan, when administered concurrently with moderate-dosage furosemide to healthy dogs, would activate the renin-angiotensin-aldosterone system (RAAS) more than furosemide alone.12 healthy dogs.6 dogs received furosem... |
|
|
Efficacy and limitations of oral inotropic agents for the treatment of chronic heart failure.
Int. Heart J. 54(2) , 75-81, (2013) The heart failure guideline in Japan has stated the necessity of investigating the role of oral inotropic agents in patients with chronic heart failure (CHF), which are clinically available only in Japan. A total of 1,846 consecutive patients with heart failu... |